Eli Lilly And Co. (LLY) News Headlines

▮ More

Date

Headline

3/22/2023 2:26:26 AM Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Disease

3/16/2023 10:26:18 PM Sanofi To Cut U.S. List Price Of Its Most-prescribed Insulin By 78%

3/8/2023 8:41:44 PM Lilly's Solanezumab Fails In Alzheimer's Prevention Trial

3/8/2023 9:36:12 AM Lilly : FDA Accepts SNDA For Jardiance For Children 10 Years & Older With Type 2 Diabetes

3/8/2023 9:03:42 AM Lilly : FDA Accepts SNDA For Jardiance For Children 10 Years And Older With Type 2 Diabetes

3/1/2023 8:40:49 AM Eli Lilly Announces Aggressive Price Cuts For Insulins; Announces Expansion Of Insulin Value Program

3/1/2023 8:01:50 AM Lilly Announces Price Reductions Of 70% For Its Most Commonly Prescribed Insulins

2/13/2023 6:01:18 AM Lilly And IABL Collaborate To Ensure Patient Access To High-Quality Affordable Insulin In Bangladesh

2/2/2023 7:07:35 AM Lilly Lifts FY23 Earnings View Above Market On Updated Tax Rate - Update

2/2/2023 6:49:22 AM Eli Lilly And Co. (LLY) Has Raised Its FY23 EPS Estimate To 8.35 - 8.55 From 8.10 - 8.30

2/2/2023 6:48:23 AM Eli Lilly And Co. Reveals Rise In Q4 Bottom Line

2/2/2023 6:46:19 AM Lilly Q4 EPS Up 13% To $2.14 On Reported Basis And Down 4% To $2.09 On Non-GAAP Basis

2/2/2023 6:00:18 AM Eli Lilly And Co. Q4 22 Earnings Conference Call At 10:00 AM ET

1/24/2023 6:40:39 AM Lilly To Expand Manufacturing Facility In North Carolina

1/24/2023 6:31:25 AM Lilly Plans To Invest Addl $450 Mln At Manufacturing Site In Research Triangle Park; To Create At Least 100 New Jobs

1/20/2023 9:24:40 AM Eli Lilly Announces FDA Acceptance Of SNDA For Jardiance For Chronic Kidney Disease

1/20/2023 9:01:58 AM Lilly : FDA Accepts SNDA For Jardiance For Adults With Chronic Kidney Disease

1/19/2023 8:03:10 PM FDA Declines To Grant Accelerated Approval To Lilly's Alzheimer's Drug

12/22/2022 6:20:36 AM Lilly, ProQR To Expand Licensing And Collaboration Deal For New Genetic Medicines

12/22/2022 6:02:54 AM Lilly, ProQR To Expand Licensing And Collaboration Agreement Focused On New Genetic Medicines